New Mesothelioma Immunotherapy Clinical Trial Opens at MD Anderson
The acclaimed MD Anderson Cancer Center in Houston is opening a phase II clinical trial involving a new immunotherapy drug aimed specifically at advanced, rare cancers, including both pleural and peritoneal mesothelioma. This single-institution clinical trial will be measuring the safety and effectiveness of vudalimab, also known as XmAb20717, which was designed by the California-based biopharmaceutical company Xencor. Vudalimab’s uniqueness stems from its ability to block the activation of cell surface proteins PD-1 and CTLA-4. These proteins stop the immune system from working properly and promote T-cell acti...
Source: Asbestos and Mesothelioma News - May 11, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Source Type: news

Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1
(MedPage Today) -- NEW ORLEANS -- Nivolumab (Opdivo) plus ipilimumab (Yervoy) improved outcomes compared with ipilimumab alone for patients with advanced melanoma who have primary resistance to PD-1 inhibitors, a randomized study found. While... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 13, 2022 Category: Dermatology Source Type: news

Nivolumab Combo Treats Advanced Esophageal Squamous - Cell Carcinoma
Overall survival longer in patients receiving first - line treatment with nivolumab plus chemo or nivolumab plus ipilimumab versus chemo alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 3, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Journal, Source Type: news

Nivolumab Combo Treats Advanced Esophageal Squamous-Cell Carcinoma
THURSDAY, Feb. 3, 2022 -- For patients with previously untreated, advanced esophageal squamous cell carcinoma, treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab results in significantly longer overall survival than chemotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 3, 2022 Category: Pharmaceuticals Source Type: news

NCI Opens New Immunotherapy Clinical Trial for Mesothelioma
This study offers a reasonable chance of benefit. It would be nice to see if these patients again respond to immunotherapy.” The FDA approved Opdivo and Yervoy, an immunotherapy combination, for first-line treatment of pleural mesothelioma in 2020. It was the first new systemic approval in more than 16 years. However, it only increased the median overall survival time from 14.1 months to 18.1 months, when compared to standard chemotherapy. Find Immunotherapy Clinical Trials ...
Source: Asbestos and Mesothelioma News - January 4, 2022 Category: Environmental Health Authors: Chris Elkins Source Type: news

Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy
This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy. The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group. More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significan...
Source: Asbestos and Mesothelioma News - December 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Clinical Trial to Involve Drug Studied for COVID-19
A novel phase II clinical trial for malignant mesothelioma is expected to open soon and involve a versatile, biological drug already showing promise in treating severe cases of COVID-19. Oncotelic Therapeutics Inc., an innovative, immunotherapy/oncology company in Agoura Hills, California, hopes to open the mesothelioma clinical trial by March at a dozen prominent U.S. treatment centers, including the Cleveland Clinic Cancer Center, University of Pennsylvania Medicine in Philadelphia and Fred Hutchinson Cancer Research Center in Seattle. “We’re excited about the potential. There is a huge unmet medical need with ...
Source: Asbestos and Mesothelioma News - December 7, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Study Supports Opdivo as Second-Line Mesothelioma Treatment
When the effectiveness of first-line chemotherapy fails and malignant mesothelioma returns, more patients could soon turn with confidence to a proven, second-line treatment. The first phase III, placebo-controlled, double-blind clinical trial studying the safety and efficacy of Opdivo, the immunotherapy drug known generically as nivolumab, has raised the level of confidence in this option for patients with relapsed disease. “The evidence is robust, the survival significant,” Dr. Dean Fennell, chair of Thoracic Medical Oncology, University of Leicester and University Hospitals in the United Kingdom, told The Mesot...
Source: Asbestos and Mesothelioma News - November 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making it t...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Nivo/Ipi Combo Now'Standard of Care' in Mesothelioma Nivo/Ipi Combo Now'Standard of Care' in Mesothelioma
Patients with malignant pleural mesothelioma have a marked and sustained overall survival benefit with nivolumab and ipilimumab vs chemotherapy, even if they discontinue treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the time of diagnos...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Ramucirumab Shows Survival Benefits with Pleural Mesothelioma
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - September 13, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Treatment Program Expanding in Central Florida
When he first joined AdventHealth Orlando in 2019, thoracic surgeon Dr. Marcelo DaSilva wondered just how successful he could be in creating a mesothelioma specialty center in Central Florida. Now he knows. DaSilva was initially hoping to create a program that would allow Florida mesothelioma patients to stay closer to home – instead of traveling across the country – and still get the best possible treatment for this rare, tough-to-treat malignancy. But he’s already done considerably more. His vision has grown, and so has his program. More patients will benefit greatly. DaSilva recently expanded his progr...
Source: Asbestos and Mesothelioma News - September 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease
We report the first real-world evidence regarding clinical outcomes for a cohort of patients with advanced MPeM receiving ICIs,” the MD Anderson study authors wrote. “Our results provide much-needed data supporting the role of ICIs in patients with this rare disease, who cannot participate in clinical trials and otherwise have no or limited treatment options.” The post Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - August 31, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers Study New Immunotherapy Combination for Mesothelioma
The immunotherapy combination of tremelimumab and durvalumab has shown surprising efficacy, particularly as a second-line treatment option for patients with pleural mesothelioma, according to a recent study. Its effectiveness, comparable to a similar combination which was approved in 2020 by the U.S. Food and Drug Administration, further illustrated the new direction for future treatment of mesothelioma. Chemotherapy will no longer be the stand-alone, standard-of-care treatment for most patients. “Promising results have emerged on the use of targeted treatment with immune checkpoint inhibitors (ICI), particularl...
Source: Asbestos and Mesothelioma News - August 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news